Sponsor: Calithera Biosciences, Inc.
Protocol CX-839-005: A placebo controlled study of CB-839 plus everolimus verses placebo plus everolimus in patients with a clear cell renal cell carcinoma that have previously been treated with anti- PD1/PDL1 therapy and a VEGFR targeting tyrosine kinase inhibitor.